基因中心DNA测序揭示系统性红斑狼疮患者的分子通路
该研究对958例瑞典SLE患者和1026名健康对照的1832个候选免疫通路基因进行测序,通过通路聚合和单变异关联分析及通路多基因风险评分(PRS),识别出T淋巴细胞分化和天然免疫两个独立易感通路,并可将患者分层为四个分子亚组。
要点
- T淋巴细胞分化和天然免疫是SLE易感的两个独立通路,分别以HLA和干扰素为特征。
- 通路PRS可定义个体患者通路状态,患者平均阳性7条通路。
- T或B细胞受体信号通路阳性的患者器官损害更明显。
核心结论
- 通路风险评分有潜力在临床表现之外将SLE患者分层为分子亚组,可能影响临床随访和治疗选择。
研究设计与样本
- 通路中心方法,对958例瑞典SLE患者和1026名健康个体的1832个候选免疫通路基因进行测序,行聚合和单变异关联检验并生成通路多基因风险评分(PRS)。
主要发现
- 识别出两个主要独立SLE易感通路:T淋巴细胞分化和天然免疫,分别以HLA和干扰素为特征。
- 通路PRS定义个体患者通路,患者平均阳性7条通路。
- T或B细胞受体信号通路阳性的患者SLE器官损害更明显。
- 基于通路PRS的聚类将患者分层为四组,风险评分谱不同。
- 在既往报道的单基因SLE基因及干扰素病基因上观察到常见变异对SLE的聚合贡献。
临床怎么用
- 通路PRS有望在临床特征之外将SLE患者分层为分子亚组,辅助临床随访和治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Systemic lupus erythematosus (SLE) is an autoimmune disease with extensive heterogeneity in disease presentation between patients, which is likely due to an underlying molecular diversity. Here, we aimed at elucidating the genetic aetiology of SLE from the immunity pathway level to the single variant level, and stratify patients with SLE into distinguishable molecular subgroups, which could inform treatment choices in SLE. METHODS: We undertook a pathway-centred approach, using sequencing of immunological pathway genes. Altogether 1832 candidate genes were analysed in 958 Swedish patients with SLE and 1026 healthy individuals. Aggregate and single variant association testing was performed, and we generated pathway polygenic risk scores (PRS). RESULTS: We identified two main independent pathways involved in SLE susceptibility: T lymphocyte differentiation and innate immunity, characterised by HLA and interferon, respectively. Pathway PRS defined pathways in individual patients, who on average were positive for seven pathways. We found that SLE organ damage was more pronounced in patients positive for the T or B cell receptor signalling pathways. Further, pathway PRS-based clustering allowed stratification of patients into four groups with different risk score profiles. Studying sets of genes with priors for involvement in SLE, we observed an aggregate common variant contribution to SLE at genes previously reported for monogenic SLE as well as at interferonopathy genes. CONCLUSIONS: Our results show that pathway risk scores have the potential to stratify patients with SLE beyond clinical manifestations into molecular subsets, which may have implications for clinical follow-up and therapy selection.
引用
- Sandling JK, Pucholt P, Hultin Rosenberg L, et al. Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing. Ann Rheum Dis. 2020. PMID: 33037003. doi:10.1136/annrheumdis-2020-218636
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。